NEW YORK (TheStreet) -- Jazz Pharmaceuticals (JAZZ) "did not hit the numbers, so the stock is down," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment.
The company missed analysts' estimates for its top- and bottom-line results. Cramer said he's highlighting Jazz Pharmaceuticals because of how poorly biotechnology stocks have performed over the past two months.
Turning to WhiteWave Foods (WWAV), "I thought that quarter was amazing," he said of the company's top and bottom line earnings beat.
He added that Hain Celestial Group (HAIN) is also doing very well, and its CEO Irwin Simon is "too clever" for the short-sellers.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts